ArticleImmunity2015
OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response.
Article in Immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 220 citations in OpenAlex.
- Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage.The Journal of allergy and clinical immunology · 2019Trial
- Article
- A CD40-OX40 co-stimulatory circuit orchestrates protective CD4Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- M5542, a bifunctional fusion protein targeting CD80, CD86, and OX40L that modulates excessive T-cell activity: a preclinical proof-of-concept study.Frontiers in immunology · 2026Article
- OX40 signaling in cancer immunotherapy: mechanisms of action, translational applications, and therapeutic perspectives.Frontiers in immunology · 2026Review
- Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy.Frontiers in medicine · 2026Review
- Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025Review
- Promising Molecular Therapeutic Targets for Drug Development in Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.The journal of allergy and clinical immunology. Global · 2025Article
- IL-1β signaling modulates T follicular helper and regulatory cells in human lymphoid tissues.JCI insight · 2025Article
- Review
- T cell-B cell interactions in human autoimmune diseases.Current opinion in immunology · 2025Review
- OX40 ligand promotes follicular helper T cell differentiation and development in mice with immune thrombocytopenia.Journal of Zhejiang University. Science. B · 2025Article
- Pharmacological Mechanism of Chinese Medicine in Systemic Lupus Erythematosus: A Narrative Review.Chinese journal of integrative medicine · 2025Review
- The role of BATF in immune cell differentiation and autoimmune diseases.Biomarker research · 2025Review
- Follicular helper T cells (Tfh): heterogeneity in spatial distribution and phenotypic characteristics.Frontiers in immunology · 2025Review
- Exploring the Mechanism of Shen Qi Gui Oral Liquid against Chemotherapy- Induced Myelosuppression in Cancer Patients Based on Network Pharmacology and Molecular Docking.Combinatorial chemistry & high throughput screening · 2025Article
- Review
- Human OX40L-CAR-TScience translational medicine · 2024Article
- Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis.The Journal of clinical endocrinology and metabolism · 2024Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 6 institutions in 2 countries.
Funding
Abstract
Increased activity of T follicular helper (Tfh) cells plays a major pathogenic role in systemic lupus erythematosus (SLE). However, the mechanisms that cause aberrant Tfh cell responses in SLE remain elusive. Here we showed the OX40 ligand (OX40L)-OX40 axis contributes to the aberrant Tfh response in SLE. OX40L was expressed by myeloid antigen-presenting cells (APCs), but not B cells, in blood and in inflamed tissues in adult and pediatric SLE patients. The frequency of circulating OX40L-expressing myeloid APCs positively correlated with disease activity and the frequency of ICOS(+) blood Tfh cells in SLE. OX40 signals promoted naive and memory CD4(+) T cells to express multiple Tfh cell molecules and were sufficient to induce them to become functional B cell helpers. Immune complexes containing RNA induced OX40L expression on myeloid APCs via TLR7 activation. Our study provides a rationale to target the OX40L-OX40 axis as a therapeutic modality for SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.